Jared J Gartner
Overview
Explore the profile of Jared J Gartner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
5032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leko V, Groh E, Levi S, Copeland A, White B, Gasmi B, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800378
Background: The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. For the treatment...
2.
Parkhurst M, Goff S, Lowery F, Beyer R, Halas H, Robbins P, et al.
Nat Med
. 2024 Jul;
30(9):2586-2595.
PMID: 38992129
Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors (TCRs) from tumor-infiltrating lymphocytes of patients with metastatic gastrointestinal...
3.
Levin N, Kim S, Marquardt C, Vale N, Yu Z, Sindiri S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816232
Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often...
4.
Mikkilineni L, Natrakul D, Lam N, Manasanch E, Mann J, Weissler K, et al.
Mol Ther
. 2023 Dec;
32(2):503-526.
PMID: 38155568
Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen receptor (CAR) with a...
5.
Yossef R, Krishna S, Sindiri S, Lowery F, Copeland A, Gartner J, et al.
Cancer Cell
. 2023 Dec;
41(12):2154-2165.e5.
PMID: 38039963
Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell clones from 6...
6.
Chatani P, Lowery F, Parikh N, Hitscherich K, Yossef R, Hill V, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37258038
Background: Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of T cells with...
7.
White B, Sindiri S, Hill V, Gasmi B, Nah S, Gartner J, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37045473
Background: Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is associated with dismal prognosis. In a...
8.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, et al.
Clin Cancer Res
. 2023 Feb;
29(12):2250-2265.
PMID: 36749875
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated...
9.
Palmer D, Webber B, Patel Y, Johnson M, Kariya C, Lahr W, et al.
Med
. 2022 Aug;
3(10):682-704.e8.
PMID: 36007524
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell effector function and neoantigen recognition may therefore improve TIL...
10.
Kim S, Vale N, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):932-946.
PMID: 35749374
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of...